Triple-Drug cocktail targets stomach cancer that has spread to the abdomen

NCT ID NCT07149090

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs—lenvatinib, nivolumab, and chemotherapy—in people with advanced stomach cancer that has spread to the lining of the abdomen and caused fluid buildup (ascites). The goal is to see if this triple therapy can shrink tumors and help patients live longer without the cancer getting worse. The trial is enrolling 61 participants and includes two phases: first to find the safest dose, then to measure how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

lenvatinib, nivolumab, and chemotherapy (capecitabine + oxaliplatin)

What this could lead to

If successful, this combination could offer a new treatment option for people with advanced gastric cancer and malignant ascites, potentially slowing disease progression and extending life.

What could go wrong

This is an early-phase trial (Phase 1/2) with only 61 participants, so results are preliminary. The drug combination may cause significant side effects, and it is not yet known if it will work better than standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••